Related Experiment Video
Updated: Sep 28, 2025
Rapid Antibody Glycoengineering in Chinese Hamster Ovary Cells
Published on: June 2, 2022
Key benefits of dexamethasone and antibody treatment in COVID-19 hamster models revealed by single-cell
Emanuel Wyler1, Julia M Adler2, Kathrin Eschke3
1Berlin Institute for Medical Systems Biology (BIMSB), Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.
Abstract:
For coronavirus disease 2019 (COVID-19), effective and well-understood treatment options are still scarce. Since vaccine efficacy is challenged by novel variants, short-lasting immunity, and vaccine hesitancy, understanding and optimizing therapeutic options remains essential. We aimed at better understanding the effects of two standard-of-care drugs, dexamethasone and anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies, on infection and host responses. By using two COVID-19 hamster models, pulmonary immune responses were analyzed to characterize effects of single or combinatorial treatments. Pulmonary viral burden was reduced by anti-SARS-CoV-2 antibody treatment and unaltered or increased by dexamethasone alone. Dexamethasone exhibited strong anti-inflammatory effects and prevented fulminant disease in a severe disease model. Combination therapy showed additive benefits with both anti-viral and anti-inflammatory potency. Bulk and single-cell transcriptomic analyses confirmed dampened inflammatory cell recruitment into lungs upon dexamethasone treatment and identified a specifically responsive subpopulation of neutrophils, thereby indicating a potential mechanism of action. Our analyses confirm the anti-inflammatory properties of dexamethasone and suggest possible mechanisms, validate anti-viral effects of anti-SARS-CoV-2 antibody treatment, and reveal synergistic effects of a combination therapy, thus informing more effective COVID-19 therapies.
Insights
This study investigated dexamethasone and anti-SARS-CoV-2 antibody treatments for COVID-19 in hamsters. Combination therapy demonstrated synergistic anti-viral and anti-inflammatory effects, suggesting improved COVID-19 treatment strategies.
Area of Science:
- Immunology and Virology
- Pharmacology and Therapeutics
Background:
- Effective treatments for coronavirus disease 2019 (COVID-19) remain limited.
- Vaccine limitations necessitate the development of robust therapeutic options.
- Understanding drug interactions is crucial for optimizing COVID-19 management.
Purpose of the Study:
- To evaluate the effects of dexamethasone and anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies on COVID-19.
- To analyze pulmonary immune responses to single and combined therapeutic interventions.
- To elucidate potential mechanisms of action for dexamethasone and combination therapy.
Main Methods:
- Utilized two distinct COVID-19 hamster models.
- Administered single and combinatorial treatments of dexamethasone and anti-SARS-CoV-2 antibodies.
- Conducted bulk and single-cell transcriptomic analyses of pulmonary immune responses.
Main Results:
- Anti-SARS-CoV-2 antibodies reduced viral load; dexamethasone showed anti-inflammatory effects and prevented severe disease.
- Combination therapy exhibited additive anti-viral and anti-inflammatory benefits.
- Dexamethasone treatment suppressed inflammatory cell recruitment, particularly neutrophils, in the lungs.
Conclusions:
- Dexamethasone possesses significant anti-inflammatory properties with potential mechanistic insights.
- Anti-SARS-CoV-2 antibodies effectively reduce viral burden.
- Combination therapy offers synergistic advantages, informing the development of enhanced COVID-19 treatments.
More Related Videos
06:03Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays
Published on: September 20, 2024
08:21Cell-Free Dot Blot as a Practical and Adaptable Immunoassay Platform for the Detection of Antibody Response in Human and Animal Sera
Published on: May 23, 2025